Core Viewpoint - TOMI Environmental Solutions, Inc. has filed a $50 million universal shelf registration statement with the SEC to enhance its financial flexibility for operational growth and strategic initiatives [1][2]. Financial Strategy - The registration statement will allow TOMI to offer and sell securities as needed, providing the company with the ability to efficiently access capital [2]. - TOMI has entered into a strategic advisory and placement arrangement with Bancroft Capital and established an equity line of credit (ELOC) facility with Hudson Global Ventures, allowing the sale of up to $20 million of common stock over a 24-month period [3]. Operational Performance - The CEO of TOMI highlighted strong sequential revenue growth and improved gross margins in Q3, indicating expanding customer adoption of the SteraMist® technology [4]. - The financing from the ELOC is intended to accelerate investments in innovation, manufacturing efficiency, and global distribution [4]. Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination through its Binary Ionization Technology® (BIT™) platform, which utilizes a low percentage of Hydrogen Peroxide to create a germ-killing aerosol [5]. - The company's products are designed for a wide range of commercial structures, including hospitals, cruise ships, schools, and military facilities [6].

Financial Data and Key Metrics Changes - In Q3 2025, the company's revenue was $2 million, a 24% decrease from $2.5 million in Q3 2024, primarily due to a timing reduction in iHP services sales from a key customer [9][10] - Year-to-date service demand remains robust, with quote activity and pipeline volume up approximately 35% year-over-year in life sciences and food safety [10] - Gross profit margins remained strong at 61% for Q3 2025, consistent with the same period last year [10] Business Line Data and Key Metrics Changes - Recurring BIT solution sales increased by 21% year-to-date, contributing to the overall revenue growth [5][10] - The sales order backlog was $0.9 million at the quarter end and grew to $1.3 million by October 31, with approximately $3 million in pending SteraMist integration contracts expected to close before year-end [6][10] Market Data and Key Metrics Changes - The FDA's broadened approval of hydrogen peroxide positions the company to serve not only life sciences and healthcare but also agriculture, food processing, and environmental biosafety [7][23] - The active pipeline surpassed $15 million, encompassing both domestic and international customers across various industries [6] Company Strategy and Development Direction - The company aims to enhance customer engagement and expand its recurring revenue streams through personalized outreach and targeted marketing campaigns [8] - Focus on biosecurity advancements and scaling automation integrations for high-efficacy environments is prioritized for 2026 [8][9] - The company is investing in innovation and customer success to capture opportunities in clean tech and biosecurity [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's recovery and reaffirmed the soundness of its strategy, with steady improvement expected financially, operationally, and strategically [25][26] - The company is well-positioned for a successful fourth quarter with momentum carrying into 2026, supported by a recent equity purchase agreement to access capital [26][27] Other Important Information - The company celebrated a significant addition to its customer roster with Bausch + Lomb, which adopted mobile handheld surface units and committed to BIT Solution orders for 2026 [19][20] - The company is actively pursuing the cannabis market and has opened doors to promising new partnership discussions [22] Q&A Session Summary Question: What are your sales and marketing efforts towards the FDA approval for hydrogen peroxide usage? - Management indicated that the food industry could be a key marketing vertical, and they are excited about the approval as it positions their technology favorably [29] Question: Should we expect operating expenses and gross margins to continue improving? - Management expects operating expenses to increase but remain positive in relation to revenue, with gross margins expected to hold steady [30][31] Question: What kind of sales effort is in place for international markets like Morocco? - The company has distributors in various countries and is working with global partners to increase demand for SteraMist [34] Question: Do you have visibility on solution sales in the coming quarters? - Management noted that while there was a decrease in solution sales growth in Q3, they expect a rebound by the end of the fourth quarter [35] Question: Any updates on servicing military and defense markets? - Management mentioned ongoing studies with a key site looking to replace formaldehyde, with expectations for significant developments in 2026 [42] Question: Any progress in the use of SteraMist for replacing ethylene oxide in medical sterilization? - Management confirmed ongoing discussions and prioritization of partnerships in device manufacturing for this purpose [51]

Financial Data and Key Metrics Changes - In Q3 2025, the company's revenue was $2 million, a 24% decrease from $2.5 million in Q3 2024, primarily due to a timing reduction in IHP services sales from a key customer [9][10] - Year-to-date service demand remains robust, with quote activity and pipeline volume up approximately 35% year over year in the life sciences and food safety areas [10] - Gross profit margins remained strong at 61% for Q3 2025, consistent with the same period last year [10] Business Line Data and Key Metrics Changes - Recurring BIP solution sales increased by 21% year to date, contributing to the overall revenue growth [5][10] - The sales order backlog was $0.9 million at the quarter end and grew to $1.3 million by October 31, with approximately $3 million in pending SteraMist integration contracts expected to close before year-end [6][10] Market Data and Key Metrics Changes - The FDA's broadened approval of hydrogen peroxide as a safe disinfectant opens new markets, particularly in food processing and agriculture [7][23] - The company is seeing strong interest from emerging sectors, with an active pipeline surpassing $15 million [6][7] Company Strategy and Development Direction - The company aims to grow sales of mobile capital equipment, IHP corporate service, and custom integration platforms alongside its core BIP solution business model [5][8] - There is a focus on biosecurity advancements and scaling automation integrations for high-efficacy environments, addressing global challenges [8][9] Management's Comments on Operating Environment and Future Outlook - Management believes the third quarter marked a decisive turning point, with a 95% sequential revenue increase driven by expanding recurring revenue streams [4][5] - The company is optimistic about the future, with a strong sales backlog and a sales strategy beginning to deliver promising results [25][26] Other Important Information - The company entered into an equity purchase agreement with Hudson Global Ventures, allowing it to sell up to $20 million in common stock over a 24-month period [26] - The SteraMist IHP technology was named the Disinfection and Decontamination Products Company of the Year 2025 [7] Q&A Session Summary Question: What are the sales and marketing efforts towards the FDA approval for hydrogen peroxide usage? - Management sees the food industry as a key marketing vertical and is excited about the approval, which is expected to be a game changer [29] Question: Should operating expenses and gross margins continue to improve? - Management expects operating expenses to increase but believes they will be positive in relation to revenue, with gross margins remaining stable [30][31] Question: What kind of sales effort is in place for international markets like Morocco? - The company has different distributors in various countries and is working with global partners to increase demand for SteraMist [34] Question: What visibility is there on solution sales in the coming quarters? - Management anticipates that solution sales will increase as more technology is deployed, with a key focus on driving growth in BIP solution sales [35] Question: Any updates on servicing military and defense markets? - The company is working with a key site looking to replace formaldehyde and expects significant developments in 2026 [42] Question: Any progress in the use of SteraMist for replacing ethylene oxide in medical instrument sterilization? - The company is prioritizing partnerships in device manufacturing to streamline IHP into decontamination processes [51]

Financial Data and Key Metrics Changes - In Q3 2025, the company's revenue was $2 million, a 24% decrease from $2.5 million in Q3 2024, primarily due to a timing reduction in IHP services sales from a key customer [9][10] - Year-to-date service demand remains robust, with quote activity and pipeline volume up approximately 35% year over year in the life sciences and food safety areas [10] - Gross profit margins remained strong at 61% for Q3 2025, consistent with the same period last year [10] Business Line Data and Key Metrics Changes - Recurring BIP solution sales increased by 21% year to date, indicating a positive trend in this segment [5][10] - The sales order backlog was $0.9 million at the quarter end and grew to $1.3 million by October 31, with approximately $3 million in pending SteraMist integration contracts expected to close before year-end [6][10] Market Data and Key Metrics Changes - The FDA's broadened approval of hydrogen peroxide as a safe disinfectant opens new markets, particularly in food safety, agriculture, and environmental biosafety [7][23] - The company is seeing strong interest from emerging sectors, with an active pipeline surpassing $15 million [6] Company Strategy and Development Direction - The company aims to grow sales of mobile capital equipment, IHP corporate service, and custom integration platforms alongside its core BIP solution business model [5] - There is a focus on biosecurity advancements and scaling automation integrations for high-efficacy environments, addressing global challenges [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's recovery and strategic execution, highlighting steady improvement financially, operationally, and strategically [25] - The company is well-positioned for a successful fourth quarter with momentum carrying into 2026, supported by a recent equity purchase agreement to access capital [26] Other Important Information - The company has been recognized as the Disinfection and Decontamination Products Company of the Year 2025, validating its solutions and positioning [7] - The company is expanding its training programs and customer engagement strategies to enhance market penetration [8] Q&A Session Summary Question: What are the sales and marketing efforts towards the FDA approval for hydrogen peroxide? - Management indicated that the food industry could be a key marketing vertical, and they are excited about the approval as it positions their technology favorably [30] Question: Should we expect operating expenses and gross margins to continue improving? - Management expects operating expenses to increase but remain positive in relation to revenue, with gross margins holding steady [31][32] Question: What kind of sales effort is in place for international markets like Morocco? - The company has distributors in various countries focused on increasing demand for SteraMist [36] Question: Do you have visibility on solution sales in the coming quarters? - Management noted that while they had a 40% increase in solution sales earlier in the year, they expect recurring sales to rise again by the end of Q4 [37] Question: Any updates on servicing military and defense markets? - Management mentioned ongoing studies with a key site looking to replace formaldehyde, expecting significant developments in 2026 [43] Question: Progress on CAR T-cell disinfection business? - No updates were provided on this front [45] Question: Expectations on the rollout by major service provider companies in healthcare mold remediation? - Management expressed optimism about rapid rollouts due to strong initial assessments and training support [46] Question: Plans to penetrate the disinfection market for data centers? - Management acknowledged the interest in data centers and the need for disinfection, indicating plans to expand the sales team for this vertical [49] Question: How is the company increasing awareness for the food industry post-FDA ruling? - The company is focusing on social media and reaching out to existing contacts in the food safety sector [51] Question: Any progress in using SteraMist for replacing ethylene oxide in medical sterilization? - Management confirmed ongoing discussions and prioritization of partnerships in this area [54]

Core Insights - TOMI Environmental Solutions, Inc. reported a significant sequential revenue increase of 95% in Q3 2025, driven by higher equipment purchases and strong recurring sales of its BIT™ Solution [5][10] - The company is strategically positioned for long-term growth, with ongoing investments in R&D and expanding international market penetration [10][11] Financial Performance - Revenues for Q3 2025 were $2.0 million, a 95% increase from Q2 2025, but a decrease from $2.54 million in Q3 2024 [5][25] - Gross profit margin remained stable at 61% for Q3 2025, indicating operational efficiency [5][25] - Operating loss for Q3 2025 was $(321,000), compared to an operating income of $149,000 in Q3 2024 [5][25] - Net loss for Q3 2025 was $(450,000) or $(0.02) per share, compared to a net income of $59,000 or $0.00 per share in Q3 2024 [5][25] Business Highlights - The company achieved a 21% year-over-year increase in SteraMist solution sales for the nine months ended September 30, 2025 [5] - International revenue accounted for nearly 36% of Q3 revenue, up from 20% in Q2 2025, reflecting successful global market penetration [5] - The sales order backlog grew to $0.9 million at quarter-end and expanded to $1.3 million by October 31, with approximately $3 million in pending contracts expected to close before year-end [5] Strategic Initiatives - The company is focusing on expanding its product applications across various sectors, including life sciences, healthcare, food safety, and commercial markets [5][10] - A new equity line of credit allows the company to sell up to $20 million in common stock over a 24-month period, enhancing financial flexibility [8][9] - The FDA's expanded approval for hydrogen peroxide use is expected to broaden the application of SteraMist iHP technology, targeting food, agriculture, and environmental biosecurity markets [10][12] Liquidity and Capital Access - As of September 30, 2025, the company had working capital of $2.5 million, with cash used in operations improving by approximately $876,000 compared to the same period in 2024 [7] - The company completed a $535,000 convertible note financing to support growth initiatives [7] Executive Commentary - The CEO highlighted the strong revenue growth and new customer partnerships as evidence of the effectiveness of the company's strategy and execution [10] - The company is optimistic about maintaining momentum into Q4 2025 and throughout 2026, supported by a growing customer base and expanding sales [11][12]

Core Points - TOMI Environmental Solutions, Inc. will report its third quarter results for the period ending September 30, 2025, on November 14, 2025, after market close [1] - A conference call will be held on the same day at 4:30 p.m. ET to discuss the results [1] Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination solutions, utilizing its proprietary Binary Ionization Technology (BIT) platform [4] - BIT technology employs a low percentage of hydrogen peroxide as the active ingredient, utilizing patented ionized Hydrogen Peroxide (iHP) technology for superior disinfection [4] - The company's products are applicable in various sectors, including hospitals, biosafety labs, pharmaceutical facilities, commercial buildings, schools, and emergency services [4]

Core Insights - TOMI Environmental Solutions, Inc. is actively participating in the AALAS 76th National Meeting to enhance its presence in the animal research sector [1][2] - The event serves as a platform for TOMI to strengthen strategic partnerships and promote its SteraMist Integrated System (SIS) [2][3] - The company aims to leverage high-impact networking opportunities to drive the adoption of its innovative ionized Hydrogen Peroxide (iHP) technology [3][4] Company Overview - TOMI specializes in disinfection and decontamination solutions, utilizing its Binary Ionization Technology® (BIT™) platform, which is based on low percentage hydrogen peroxide [5] - The company’s products are designed for a wide range of applications, including hospitals, biosafety labs, and food processing facilities [5] Event Participation - AALAS is a significant event for TOMI, attracting thousands of professionals from research institutions, which facilitates lead generation and collaboration [3] - The executive team, including key leaders from various departments, will represent TOMI at the event, highlighting the company's commitment to innovation and customer-centric growth [4][5]

Core Insights - TOMI Environmental Solutions, Inc. has appointed Mr. Harold W. Paul to its Board of Directors, effective immediately, succeeding Ms. Kelly J. Anderson who resigned as of September 30, 2025 [1][3] Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination through its Binary Ionization Technology (BIT) platform, marketed under the SteraMist brand [1][4] - The BIT solution utilizes a low percentage of hydrogen peroxide as its active ingredient and employs patented ionized Hydrogen Peroxide (iHP) technology for superior disinfection [4] Leadership Experience - Mr. Paul brings over 40 years of legal and securities expertise, along with extensive board leadership experience across various industries, having previously served on TOMI's Board from 2009 to 2021 [2] - He has advised numerous publicly traded companies as outside legal counsel and has served on the boards of six public companies [2] Strategic Importance - The CEO of TOMI, Dr. Halden Shane, expressed that Mr. Paul's knowledge of securities law and corporate governance will provide valuable insights as the company advances its strategy and expands its impact in critical industries [3]

Core Insights - TOMI Environmental Solutions, Inc. has made a strategic move by purchasing SteraMist iHP equipment and BIT Solution worth $175,000 through T.A.C.T. franchises, marking a significant step in its commercial growth strategy [1][2][3] Group 1: Company Developments - The phased rollout of SteraMist technology by T.A.C.T. franchises indicates their confidence in its effectiveness, with initial purchases leading to widespread adoption across all participating franchises [2][3] - The integration of SteraMist iHP technology into T.A.C.T.'s operations has been seamless, supported by TOMI's customer service and educational initiatives [3][5] - The partnership with T.A.C.T. is expected to create recurring revenue opportunities for TOMI, particularly through the BIT Solution [6] Group 2: Market Opportunities - There is a growing market opportunity in addressing mycotoxin contamination, which has reportedly increased by 20-30% in the U.S. over the past decade due to various environmental factors [5] - Mycotoxins pose significant health risks and can lead to costly consequences for businesses, making SteraMist iHP technology a valuable solution for remediation [5][6] - TOMI's SteraMist technology is positioned to tackle critical challenges in public health, particularly in commercial settings where mold and mycotoxin contamination are prevalent [6]

Core Insights - TOMI Environmental Solutions, Inc. has formed a strategic alliance with Steri-Clean to enhance its franchise-focused growth strategy and address increasing biohazard challenges in the U.S. [1] - The adoption of SteraMist iHP technology by Steri-Clean aims to improve service offerings in hoarding cleanup and biohazard remediation, leveraging advanced disinfection solutions [1][2] - Steri-Clean operates approximately 60 franchises and is recognized for its expertise in handling complex cleaning scenarios, including severe clutter and hazardous materials [2] - The initial implementation of SteraPak units at Steri-Clean's franchise locations is expected to enhance service efficiency and effectiveness in disinfection [3] - The partnership aligns with TOMI's broader commercial strategy, which includes educational initiatives and customer support enhancements to tackle emerging public health issues [4] Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination solutions, utilizing its Binary Ionization Technology® (BIT™) platform [4] - The BIT™ solution employs a low percentage of hydrogen peroxide as its active ingredient, utilizing patented ionized Hydrogen Peroxide (iHP™) technology for superior disinfection [4] - TOMI's products are designed for a wide range of applications, including hospitals, biosafety labs, commercial buildings, and emergency services [4]